Valuation: Atrion Corporation

Market Cap 81Cr 70Cr 65Cr 60Cr 113.55Cr 7.73TCr 115.31Cr 772.01Cr 302.99Cr 3.85TCr 303.99Cr 297.31Cr 13TCr P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 80Cr 70Cr 65Cr 60Cr 112.71Cr 7.67TCr 114.46Cr 766.27Cr 300.74Cr 3.82TCr 301.73Cr 295.1Cr 13TCr EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
564.21
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap.
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%-15.37% 81Cr
+0.09%+2.56%-16.96%-2.69% 18TCr
-0.37%+2.62%-4.42%-0.08% 11TCr
-0.29%+0.47%+7.97%+62.64% 6.06TCr
-1.52%-1.88%+34.29%+49.25% 5.18TCr
+0.10%+5.92%-6.10%-40.04% 4.56TCr
+0.41%+1.37% - - 3.32TCr
+11.95%+16.65%+5.26%-32.60% 3.15TCr
+0.40%+3.89%+42.51%-7.99% 2.4TCr
-1.22%+6.69%+0.67%+0.26% 2.23TCr
Average +0.94%+4.37%+7.03%+1.49% 5.62TCr
Weighted average by Cap. +0.44%+3.48%-0.76%+5.28%

Financials

2022 2023
Net sales 18Cr 16Cr 15Cr 14Cr 26Cr 1.75TCr 26Cr 175.02Cr 69Cr 872.1Cr 69Cr 67Cr 2.92TCr 17Cr 15Cr 14Cr 13Cr 24Cr 1.62TCr 24Cr 161.5Cr 63Cr 804.71Cr 64Cr 62Cr 2.7TCr
Net income 3.5Cr 3.04Cr 2.83Cr 2.6Cr 4.91Cr 334.19Cr 4.99Cr 33Cr 13Cr 166.37Cr 13Cr 13Cr 557.88Cr 1.94Cr 1.69Cr 1.57Cr 1.44Cr 2.72Cr 185.3Cr 2.77Cr 19Cr 7.27Cr 92Cr 7.29Cr 7.13Cr 309.33Cr
Net Debt -2.52Cr -2.19Cr -2.04Cr -1.87Cr -3.54Cr -240.67Cr -3.59Cr -24Cr -9.44Cr -119.81Cr -9.47Cr -9.26Cr -401.75Cr -60.16L -52.3L -48.68L -44.69L -84.4L -57Cr -85.7L -5.74Cr -2.25Cr -29Cr -2.26Cr -2.21Cr -96Cr
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock